Why No One Cares About ADHD Medication Pregnancy

Why No One Cares About ADHD Medication Pregnancy

Blog Article

ADHD Medication During Pregnancy and Breastfeeding

The choice of whether to stop or continue ADHD medication during pregnancy and breastfeeding is a difficult decision for women suffering from the condition. There is a lack of information about how long-term exposure to these medications may affect the fetus.

A recent study published in Molecular Psychiatry shows that children exposed to ADHD medication in the uterus don't develop neurological developmental disorders like impaired vision or hearing seizures, febrile seizures or IQ impairment. The authors acknowledge that more high-quality research is needed.

Risk/Benefit Analysis

Pregnant women who use ADHD medications must weigh the benefits of taking them against potential risks to the fetus. Physicians do not have the information needed to make unequivocal recommendations however they can provide information about risks and benefits that help pregnant women make informed choices.

A study published in Molecular Psychiatry found that women who were taking ADHD medications in early pregnancy did not face a significantly higher risk of fetal cardiac malformations or major birth defects that are structural. Researchers used a large sample-based case control study to compare the incidence of major structural defects in infants who were born to mothers who were taking stimulants during pregnancy. Pediatric cardiologists and clinical geneticists reviewed the cases to ensure an accurate classification of the cases and to reduce the possibility of bias.

The research conducted by the researchers had some limitations. The researchers were not able in the beginning, to separate the effects caused by the medication from the disorder. This limitation makes it difficult to determine whether the limited associations observed in the exposed groups result from medication use or confounding by comorbidities. In addition the researchers did not look at long-term offspring outcomes.

The study showed that infants whose mothers had taken ADHD medication during pregnancy were at a slightly greater risk of being admitted to the neonatal care unit (NICU) as compared to mothers who didn't take any medication during pregnancy or stopped taking their medication before or during pregnancy. The reason for this was central nervous system-related disorders, and the increased risk for admission was not found to be affected by the type of stimulant medications were used during pregnancy.

Women who were taking stimulant ADHD medication during pregnancy also had an elevated chance of having a caesarean birth or having a baby born with an low Apgar score (less than 7). These increases did not seem to be influenced by the type of medication that was used during pregnancy.

The research suggests that the risk of a small amount with the use of ADHD medications during early pregnancy may be offset by the greater benefits to both mother and child of continuing treatment for the woman's disorder. Doctors should discuss with their patients about this issue and, if possible, help them develop coping strategies that can lessen the impact of her disorder in her daily functioning and her relationships.

Interactions with Medication

Doctors are increasingly faced with the decision of whether to continue treatment or stop as more women are diagnosed with ADHD. Most of the time, these decisions are made in the absence of solid and reliable evidence in either case, which means that doctors must weigh what they know about their experiences, the experiences of other doctors, and what research says on the topic as well as their own judgments for each patient.

Particularly, the issue of potential risks for the infant can be difficult. A lot of studies on this topic are based on observational data instead of controlled research and their conclusions are often contradictory. Most studies limit their analysis to live births, which can underestimate the teratogenic impact leading to terminations or abortions of pregnancy. The study that is discussed in the journal club addresses these limitations by analyzing information on deceased and live births.

Conclusion Some studies have revealed a positive correlation between ADHD medications and certain birth defects, other studies have not found a correlation. Most studies show that there is a neutral, or slightly negative, effect. In the end an accurate risk-benefit analysis is required in every case.

For women suffering from ADHD, the decision to stop taking medication can be difficult, if not impossible. In fact, in a recent article in Archives of Women's Mental Health, psychologist Jennifer Russell notes that stopping ADHD medication during pregnancy can increase depression, feelings of loneliness and family conflict for those suffering from the disorder. A loss of medication may affect the ability to drive safely and complete work-related tasks, which are essential aspects of daily life for people with ADHD.

She suggests that women who are unsure whether to continue taking medication or discontinue it due to pregnancy, educate their family members, colleagues, and their friends about the condition, the impact on daily functioning and the benefits of continuing the current treatment regimen. It can also help women feel confident about her decision. It is also worth noting that some medications are able to pass through the placenta, therefore, if a patient decides to discontinue her ADHD medication during pregnancy and breastfeeding, she must be aware that traces of the drug can be transferred to the child.

Risk of Birth Defects

As the use of ADHD medications to treat symptoms of attention deficit hyperactivity disorder (ADHD) increases as do concerns over the impact that these medications could have on foetuses. A recent study published in the journal Molecular Psychiatry adds to the body of knowledge on this subject. Researchers used two massive datasets to analyze more than 4.3 million pregnant women and determine whether stimulant medications caused birth defects. Although the risk overall remains low, the scientists discovered that the first-trimester exposure to ADHD medications was associated with an increased risk of specific heart defects, like ventriculo-septal defects (VSD).

The researchers of the study found no association between the use of early medications and other congenital anomalies, such as facial clefting or club foot. The results are in the same vein as previous studies that showed the existence of a slight, but significant increase in cardiac malformations for women who began taking ADHD medication prior to the time of pregnancy. This risk increased during the latter half of pregnancy when a large number of women stopped taking their medication.

Women who took ADHD medications during the first trimester of their pregnancy were also more likely to have caesarean sections, a low Apgar score after delivery and a baby who needed breathing assistance during birth. However the researchers of the study were unable to eliminate bias due to selection by limiting the study to women who didn't have other medical issues that could have contributed to these findings.

Researchers hope that their research will inform physicians when they see pregnant women. They advise that while a discussion of risks and benefits is important, the decision to stop or continue medication must be based on each woman's needs and the severity of her ADHD symptoms.

The authors also caution that even though stopping the medication is an option, it is not an option to consider due to the high incidence of depression and other mental health issues among women who are pregnant or recently postpartum. Further, the research suggests that women who choose to stop taking their medication are more likely to have a difficult time adapting to life without them following the baby's arrival.

Nursing

The responsibilities of a new mother can be overwhelming. Women who suffer from ADHD who must work through their symptoms while attending physician appointments, preparing for the arrival of their child and adapting to new routines in the home may face a lot of challenges. Many women opt to continue taking their ADHD medication during pregnancy.

The majority of stimulant drugs are absorbed by breast milk in low amounts, so the risk to the infant who is breastfeeding is low. However, the amount of medication exposure to the newborn may differ based on the check here dosage, frequency it is administered, and the time of day the medication is administered. Additionally, individual medications enter the body of the baby differently through the gastrointestinal tract as well as breast milk, and the effect of this on a newborn isn't fully known.

Some doctors may decide to stop stimulant medication during a woman's pregnancy due to the absence of research. This is a difficult decision for the patient, who must weigh the benefits of keeping her medication against the potential risks to the fetus. As long as more information is available, doctors can ask pregnant patients whether they have an background of ADHD or if they plan to take medication in the perinatal phase.

Numerous studies have demonstrated that women can continue taking their ADHD medication safely during pregnancy and while breast-feeding. In response, a growing number of patients are choosing to do this. They have found after consulting with their doctor that the benefits of keeping their current medication outweigh any potential risks.

Women who suffer from ADHD who plan to breastfeed should seek advice from a specialist psychiatrist before becoming pregnant. They should discuss their medication with their prescriber as well as the pros and cons of continuing treatment. This includes non-pharmacological methods. Psychoeducation is also necessary to help pregnant women with ADHD recognize the signs and underlying disorder. They should also be educated about treatment options and reinforce strategies for coping. This should be a multidisciplinary approach with the GPs, obstetricians and psychiatrists. Pregnancy counseling should include discussion of a treatment plan for the mother as well as the child, as well as monitoring for signs of deterioration and, if needed, adjustments to the medication regimen.